[go: up one dir, main page]

AR043811A1 - Vehiculos de fase unica no acuosos y formulaciones que utilizan dichos vehiculos - Google Patents

Vehiculos de fase unica no acuosos y formulaciones que utilizan dichos vehiculos

Info

Publication number
AR043811A1
AR043811A1 ARP040101085A ARP040101085A AR043811A1 AR 043811 A1 AR043811 A1 AR 043811A1 AR P040101085 A ARP040101085 A AR P040101085A AR P040101085 A ARP040101085 A AR P040101085A AR 043811 A1 AR043811 A1 AR 043811A1
Authority
AR
Argentina
Prior art keywords
drug
aqueous
vehicle
stable
drug formulation
Prior art date
Application number
ARP040101085A
Other languages
English (en)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR043811(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of AR043811A1 publication Critical patent/AR043811A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Materiales y métodos para proporcionar vehículos útiles para proveer formulaciones de droga que contrarresten las desventajas potenciales de las formulaciones no acuosas conocidas.. Vehículos no acuosos que se forman utilizando una combinación de polímero y solvente que da como resultado un vehículo que es miscible en agua. Los vehículos no acuosos facilitan la formulación de formulaciones de droga que son estables a través del tiempo, aun cuando estén almacenadas a, o expuestas a, temperaturas elevadas. Además, los vehículos miscibles de la presente permiten la preparación de formulaciones de droga que sirven para reducir la posibilidad de que tengan lugar oclusiones parciales o completas de los conductos de transferencia incluidos en los dispositivos de transferencia utilizados para administrar las formulaciones de droga. Reivindicación 1: Una formulación de droga no acuosa estable que comprende: al menos una droga; y un vehículo de fase única no acuoso que comprende al menos un polímero y al menos un solvente, siendo el vehículo miscible en agua; en la cual la droga es insoluble en uno o más componentes de vehículo y siendo la formulación de droga estable a 37s C durante al menos dos meses. Reivindicación 5 : La formulación de droga acuosa estable de acuerdo con la reivindicación 1, en la cual la droga comprende medicinas, vitaminas, nutrientes, o suplementos alimenticios. Reivindicación 6: La formulación de droga no acuosa estable de acuerdo con la reivindicación 1, en la cual la droga comprende un péptido p proteína. Reivindicación 7: La formulación de droga no acuosa estable de acuerdo con la reivindicación 1, en la cual la droga es seleccionada del grupo que consiste en hormona adrenocorticotrópica, angiotensina I y II, péptido natriurético atrial, bombesina, bradiquinina, calcitocina, cerebelina, dinorfina N, endorfina alfa y beta, endotelina, encefalina, factor de crecimiento epidémico, fertirelina, péptido liberador de gonadotropina folicular, galanina, glucagón, GLP-1, gonadorelina, gonadotropina, goserelina, pcptido liberador de hormona decrecimiento, histrelina, hormona de crecimiento humano, insulina, interferones, leuprolide, LHRH, motilina, nafarerlina, nuerotensina, oxitocina, relaxina, somatostatina, substancia P, factor de necrosis tumoral, triptorelina, vasopresina, hormona de crecimiento, factor de crecimiento nervioso, factores de coagulación de la sangre, ribozimas, y oligonucleótidos antisentido. Reivindicación 8: La formulación de droga no acuosa estable de acuerdo con la reivindicación 1, en la cual el por lo menos un polímero es seleccionado del grupo que consiste en poliésteres, pirrolidonas, ésteres de alcoholes no saturados, ésteres de alcoholes no saturados, copolímeros en bloque de polioxietileno-polioxipropileno y combinaciones de los mismos. Reivindicación 9: La formulación de droga no acuosa estable de acuerdo con la reivindicación 1, en la cual el por lo menos un solvente es seleccionado del grupo que consiste en glucofurol, tetraglicol, n-metilpirrolidona, glicerina formal, glicerina, propilenglicol y combinaciones de los mismos. Reivindicación 14: La formulación de droga no acuosa estable de acuerdo con la reivindicación 1, en la cual el vehículo comprende glucofurol como un solvente y polivinilpirrolidona como polímero. Reivindicación 15: La formulación de droga no acuosa estable de acuerdo con la reivindicación 1, en la cual el vehículo comprende alcohol bencílico como un solvente y polivinilpirrolidona como polímero. Reivindicación 18: Un dispositivo de transferencia de droga que comprende: un reservorio que tiene al menos un orificio de transferencia de droga; una formulación de droga contenida dentro del reservorio, comprendiendo la formulación de droga una droga dispersada en un vehículo no acuoso de fase única; comprendiendo el vehículo no acuoso de fase única sal menos un polímero y al menos un solvente, siendo el vehículo miscible en agua; en el cual la droga no es soluble en uno o más componentes de vehículo y la formulación de droga es estable a 37s C durante al menos dos meses. Reivindicación 19: El dispositivo de transferencia de droga de acuerdo con la reivindicación 18, en el cual el dispositivo es una bomba osmótica implantable y el reservorio comprende un agente osmótico.
ARP040101085A 2003-03-31 2004-03-31 Vehiculos de fase unica no acuosos y formulaciones que utilizan dichos vehiculos AR043811A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45930003P 2003-03-31 2003-03-31

Publications (1)

Publication Number Publication Date
AR043811A1 true AR043811A1 (es) 2005-08-17

Family

ID=33159638

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101085A AR043811A1 (es) 2003-03-31 2004-03-31 Vehiculos de fase unica no acuosos y formulaciones que utilizan dichos vehiculos

Country Status (19)

Country Link
US (3) US20050008661A1 (es)
EP (1) EP1610765B1 (es)
JP (1) JP2006522133A (es)
KR (1) KR20060002922A (es)
CN (1) CN1767815A (es)
AR (1) AR043811A1 (es)
AT (1) ATE404175T1 (es)
AU (2) AU2004227837A1 (es)
BR (1) BRPI0408925A (es)
CA (1) CA2520775A1 (es)
CL (1) CL2004000698A1 (es)
DE (1) DE602004015755D1 (es)
MX (1) MXPA05010602A (es)
NO (1) NO20054904L (es)
NZ (1) NZ542867A (es)
RU (1) RU2005133427A (es)
TW (1) TW200505500A (es)
WO (1) WO2004089335A2 (es)
ZA (1) ZA200508782B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) * 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
ATE494010T1 (de) * 2002-02-27 2011-01-15 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
WO2003105803A1 (en) * 2002-06-17 2003-12-24 Alza Corporation Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2006522133A (ja) * 2003-03-31 2006-09-28 アルザ・コーポレーション 非水性単一相の媒体、及び、そのような媒体を利用するフォーミュレーション
MXPA05010604A (es) * 2003-03-31 2005-11-23 Alza Corp Sistema de administracion osmotica y metodo para disminuir los tiempos de arranque para sistemas de administracion osmotica.
CA2520610A1 (en) * 2003-03-31 2004-10-21 Alza Corporation Osmotic pump with means for dissipating internal pressure
ES2737835T3 (es) 2003-04-23 2020-01-16 Valeritas Inc Bomba accionada hidráulicamente para la administración de medicamentos de larga duración
BRPI0416094A (pt) * 2003-10-31 2007-01-02 Alza Corp bomba osmótica com plugue de membrana de inicialização rápida, de auto-retenção
MXPA06003065A (es) * 2003-11-06 2006-05-31 Alza Corp Reductor de velocidad de imbibicion modular para uso con bomba osmotica implantable.
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US9089636B2 (en) * 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20060045891A1 (en) * 2004-08-24 2006-03-02 Lovalenti Phillip M Density-matched suspension vehicles and pharmaceutical suspensions
TW200640483A (en) * 2005-02-03 2006-12-01 Alza Corp Non-aqueous single phase vehicles and formulations utilizing such vehicles
US20060216242A1 (en) * 2005-02-03 2006-09-28 Rohloff Catherine M Suspending vehicles and pharmaceutical suspensions for drug dosage forms
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083950A2 (en) * 2005-02-03 2006-08-10 Alza Corporation Method for reducing the level of peroxides in bopcompatible polymer preparations
EP2361630A1 (en) * 2005-02-03 2011-08-31 Intarcia Therapeutics, Inc Implantable drug delivery device comprising particles and an osmotic pump
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US7959938B2 (en) * 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
US20070027105A1 (en) * 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
WO2007076371A2 (en) 2005-12-19 2007-07-05 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
EP2005309B1 (en) 2006-03-30 2016-02-17 Valeritas, Inc. Multi-cartridge fluid delivery device
DK2020990T3 (da) 2006-05-30 2010-12-13 Intarcia Therapeutics Inc Strømningsmodulator med en indre kanal til et todelt osmotisk fremføringssystem
AU2007284759B2 (en) * 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
JP5018307B2 (ja) 2006-09-26 2012-09-05 富士通株式会社 レジストパターン厚肉化材料、レジストパターンの形成方法、半導体装置及びその製造方法
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20100184698A1 (en) * 2007-09-11 2010-07-22 Dorian Bevec Use of a deslorelin and mastoparan as a therapeutic agent
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US8343140B2 (en) * 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CN102281865B (zh) * 2008-10-15 2017-04-05 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用
WO2011037623A1 (en) * 2009-09-28 2011-03-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9956287B2 (en) * 2013-02-06 2018-05-01 Perosphere Inc. Stable glucagon formulations
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US9956164B2 (en) 2014-04-16 2018-05-01 Veyx-Pharma Gmbh Veterinary pharmaceutical composition and use thereof
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA2962768C (en) 2014-10-01 2023-10-10 Alyssa M. Larson Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
EP4277702A1 (en) 2021-01-12 2023-11-22 Durect Corporation Sustained release drug delivery systems and related methods

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069251A (en) * 1969-02-08 1978-01-17 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler Continuous process for the manufacture of methionine
US3797492A (en) * 1972-12-27 1974-03-19 Alza Corp Device for dispensing product with directional guidance member
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4305927A (en) * 1979-02-05 1981-12-15 Alza Corporation Method for the management of intraocular pressure
US4304767A (en) * 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4562024A (en) * 1982-07-06 1985-12-31 Sterling Drug Inc. Process for preparing granulate containing poorly compressible medicinally active matter
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
JPS62267326A (ja) * 1986-05-15 1987-11-20 Sanyo Chem Ind Ltd ポリエ−テルの精製法
JPH0657722B2 (ja) * 1986-05-27 1994-08-03 三菱化成株式会社 水溶性ポリマ−組成物
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5219572A (en) * 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
EP0532546B1 (en) * 1990-05-10 1998-03-18 Bechgaard International Research And Development A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
GB9027422D0 (en) * 1990-12-18 1991-02-06 Scras Osmotically driven infusion device
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5221698A (en) * 1991-06-27 1993-06-22 The Regents Of The University Of Michigan Bioactive composition
US5288214A (en) * 1991-09-30 1994-02-22 Toshio Fukuda Micropump
DE4137649C2 (de) * 1991-11-15 1997-11-20 Gerhard Dingler Bauelement
US5456679A (en) * 1992-02-18 1995-10-10 Alza Corporation Delivery devices with pulsatile effect
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5368588A (en) * 1993-02-26 1994-11-29 Bettinger; David S. Parenteral fluid medication reservoir pump
US5639477A (en) * 1993-06-23 1997-06-17 Alza Corporation Ruminal drug delivery device
DE4403567A1 (de) * 1994-02-07 1995-08-10 Storz Karl Gmbh & Co Vorrichtung zur Durchführung endoskopischer Operationen mittels einer intra- und/oder extrakorporalen Hülle
US5697975A (en) * 1994-02-09 1997-12-16 The University Of Iowa Research Foundation Human cerebral cortex neural prosthetic for tinnitus
NL9401150A (nl) * 1994-07-12 1996-02-01 Nederland Ptt Werkwijze voor het aan een ontvangzijde aanbieden van een van een zendzijde afkomstig eerste aantal videosignalen, alsmede systeem, alsmede zender, alsmede netwerk, en alsmede ontvanger.
PT788351E (pt) 1994-11-10 2003-06-30 Univ Kentucky Res Foundation T Dispositivo implantavel recarregavel de libertacaocontrolada para administrar medicamentos direc tamente numa porcao interna do corpo
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
EP1249229A3 (en) * 1996-02-02 2005-02-02 ALZA Corporation Sustained delivery of an active agent using an implantable system
US6261584B1 (en) * 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) * 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6156331A (en) * 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6132420A (en) * 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US5976109A (en) * 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
DE69739165D1 (de) * 1996-07-08 2009-01-29 Penwest Pharmaceuticals Co Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
US5780431A (en) * 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6130200A (en) * 1996-12-20 2000-10-10 Alza Corporation Gel composition and methods
ZA981610B (en) * 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
US5874388A (en) * 1997-04-02 1999-02-23 Dow Corning Corporation Lubricant composition for disc brake caliper pin and a disc brake asembly containing the lubricant
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
JP3703262B2 (ja) * 1997-08-19 2005-10-05 三井化学株式会社 ポリオキシアルキレンポリオール、軟質ポリウレタンフォーム及び非発泡ポリウレタンの製造方法
JP4215188B2 (ja) * 1997-12-22 2009-01-28 インターシア セラピューティクス，インコーポレイティド 薬剤供給を調節するデバイスのための速度調節膜
ES2217613T3 (es) * 1997-12-29 2004-11-01 Alza Corporation Sistema de liberacion osmotica con mecanismo de retencion de tapon de membrana.
PT1736145E (pt) * 1997-12-30 2012-03-16 Intarcia Therapeutics Inc Sistema de entrega de agente benéfico com obturador de membrana
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6248112B1 (en) * 1998-09-30 2001-06-19 C. R. Bard, Inc. Implant delivery system
WO2000033866A1 (en) * 1998-12-04 2000-06-15 Provalis Uk Limited Pharmaceutical compositions containing insulin
ES2261190T3 (es) * 1999-02-08 2006-11-16 Alza Corporation Vehiculos viscosos no acuosos estables de fase unica y formulaciones que utilizan dichos vehiculos.
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US6541021B1 (en) 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US20030059376A1 (en) * 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
ATE464062T1 (de) * 1999-10-04 2010-04-15 Novartis Vaccines & Diagnostic Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
US6436091B1 (en) * 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
AU2092701A (en) 1999-12-17 2001-06-25 Durect Corporation Devices and methods in intracerebrospinal delivery of morphine-6-glucuronide
DK1328256T3 (da) * 1999-12-21 2006-02-20 Alza Corp Ventil til osmotiske indretninger
US6283949B1 (en) * 1999-12-27 2001-09-04 Advanced Cardiovascular Systems, Inc. Refillable implantable drug delivery pump
AU2001900A (en) * 1999-12-29 2001-07-16 Progen S.R.L. Biocompatible hydrogel and method of its production
US6572890B2 (en) 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
ES2275992T5 (es) * 2000-02-08 2011-05-18 Allergan, Inc. Composiciones farmacéuticas de toxina botulínica.
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
AU2001296770A1 (en) 2000-10-06 2002-04-15 Durect Corporation Devices and methods for management of inflammation
EP1335704A2 (en) 2000-11-16 2003-08-20 Durect Corporation Implant dosage form and use thereof for the delivery of a cholesterol lowering agent
CA2429945A1 (en) 2000-11-29 2002-06-06 Durect Corporation Devices and methods for controlled delivery from a drug delivery device
CA2448218C (en) * 2001-06-21 2012-05-29 Genentech, Inc. Sustained release formulation
US20030021841A1 (en) * 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
JP2005519873A (ja) * 2001-11-14 2005-07-07 アルザ・コーポレーション カテーテル注入可能なデポー組成物およびそれらの使用
CA2466632C (en) * 2001-11-14 2014-02-11 Alza Corporation Injectable depot compositions and uses thereof
GB2386066A (en) * 2002-02-28 2003-09-10 Norbrook Lab Ltd Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
WO2003087335A2 (en) * 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
IL166418A0 (en) * 2002-07-31 2006-01-15 Alza Corp Injectable depot compositions and uses thereof
WO2004043432A2 (en) * 2002-11-06 2004-05-27 Alza Corporation Controlled release depot formulations
CN1726008A (zh) * 2002-12-19 2006-01-25 阿尔萨公司 用于从植入装置中传递的稳定的非水单相凝胶及其制剂
JP2006522133A (ja) 2003-03-31 2006-09-28 アルザ・コーポレーション 非水性単一相の媒体、及び、そのような媒体を利用するフォーミュレーション
BRPI0416094A (pt) * 2003-10-31 2007-01-02 Alza Corp bomba osmótica com plugue de membrana de inicialização rápida, de auto-retenção
US20050118206A1 (en) 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle

Also Published As

Publication number Publication date
HK1090834A1 (en) 2007-01-05
NZ542867A (en) 2009-02-28
NO20054904L (no) 2005-12-15
AU2004227837A1 (en) 2004-10-21
CA2520775A1 (en) 2004-10-21
RU2005133427A (ru) 2006-04-27
WO2004089335A3 (en) 2005-02-10
JP2006522133A (ja) 2006-09-28
NO20054904D0 (no) 2005-10-24
US20050276856A1 (en) 2005-12-15
WO2004089335A2 (en) 2004-10-21
US8496943B2 (en) 2013-07-30
AU2010212478A1 (en) 2010-09-09
MXPA05010602A (es) 2005-11-23
US20050008661A1 (en) 2005-01-13
US20130251674A1 (en) 2013-09-26
CN1767815A (zh) 2006-05-03
TW200505500A (en) 2005-02-16
EP1610765B1 (en) 2008-08-13
DE602004015755D1 (de) 2008-09-25
BRPI0408925A (pt) 2006-04-04
CL2004000698A1 (es) 2005-05-20
KR20060002922A (ko) 2006-01-09
ZA200508782B (en) 2007-02-28
ATE404175T1 (de) 2008-08-15
EP1610765A2 (en) 2006-01-04
AU2010212478B2 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
AR043811A1 (es) Vehiculos de fase unica no acuosos y formulaciones que utilizan dichos vehiculos
US10646572B2 (en) Pharmaceutical compositions with enhanced stability
ES2359973T3 (es) Composiciones poliméricas líquidas para la liberación controlada de sustancias bioactivas.
KR100858856B1 (ko) 안정한 비수성 단일상 점성 비히클 및 그 비히클을이용하는 제형물
ES2309768T3 (es) Una formulacion que contiene una biomolecula en forma de suspension de una estabilidad aumentada y administrable a traves de un dispositivo de liberacion implantable.
ES2201306T3 (es) Formulaciones peptidicas proticas no acuosas.
US8048438B2 (en) Stable non- aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20090087408A1 (en) Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
RU2009103210A (ru) Фармацевтические композиции для доставки пептидов с замедленным высвобождением
ES2928676T3 (es) Composición farmacéutica para una liberación sostenida de lanreotida
JP2009543776A5 (es)
JP4868678B2 (ja) エレクトロポーレーション用の組成物
WO2006084140B1 (en) Method for reducing the level of peroxides in bopcompatible polymer preparations
US6721595B1 (en) Percutaneous absorption promoters for electroporation
CN105579055A (zh) Lhrh类似物的水性缓释组合物
KR20030076685A (ko) 일렉트로포레이션용 조성물
WO2001026689A1 (fr) Compositions d'electroporation
AR133175A1 (es) Formulaciones poliméricas de acetato de leuprolida
BRPI0706558B1 (pt) Composição polimérica injetável, métodos para preparar uma composição polimérica injetável e métodos para preparar um sal de um análogo de hormônio de liberação de hormônio luteínico (lhrh)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal